The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo

International Journal of Molecular Medicine

Volumn 30, Issue 5, 2012, Pages 1087-1094

  Zhu, Hong ^a   Zhao, Fen ^b   Yu, Shuijing ^b,c   He, Jianping ^a   Deng, Licong ^b   Yi, Cheng ^a   Huang, Ying ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c Shenyang Xin Zhuoyue Machinery Import and Export Company Limited   (China)

Author keywords

Apoptosis; Colon carcinoma; Irinotecan; Synergism; TRAIL receptor; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

CASPASE 9; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DNA; IRINOTECAN; MESSENGER RNA; PROTEIN BAX; SULFORHODAMINE B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL STRAIN; CELL VIABILITY; COLON CARCINOMA; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2-ASSOCIATED X PROTEIN; CAMPTOTHECIN; CARCINOMA; CASPASE 9; CELL SURVIVAL; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HT29 CELLS; HUMANS; MICE; MICE, NUDE; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866627367     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1105     Document Type: Article

References (34)

1. Oosterling SJ, van der Bij GJ, Bogels M, ten Raa S, Post JA, Meijer GA, Beelen RH and van Egmond M: Anti-beta1 integrin antibody reduces surgery-induced adhesion of colon carcinoma cells to traumatized peritoneal surfaces. Ann Surg 247: 85-94, 2008.
2. Hennebelle I, Terret C, Chatelut E, Bugat R, Canal P and Guichard S: Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity. Anticancer Drugs 11: 465-470, 2000.
3. Saetern AM, Brandl M, Bakkelund WH and Sveinbjornsson B: Cytotoxic effect of different camptothecin formulations on human colon carcinoma in vitro. Anticancer Drugs 15: 899-906, 2004. (Pubitemid 39482931)
4. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS and Sanlioglu S: High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. Pancreas 38: 154-160, 2009.
5. Ashkenazi A, Holland P and Eckhardt SG: Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26: 3621-3630, 2008.
6. Yoo J, Park SS and Lee YJ: Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells. J Cell Biochem 104: 1636-1646, 2008.
7. Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, Wang W and Buchsbaum DJ: Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin Cancer Res 14: 2180-2189, 2008. (Pubitemid 351551131)
8. Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, Mayer EG, Yu H, Pardoll DM, Ashkenazi A and Bedi A: Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/ TRAIL. Cancer Res 64: 9105-9114, 2004. (Pubitemid 39665525)
9. Sugamura K, Gibbs JF, Belicha-Villanueva A, Andrews C, Repasky EA and Hylander BL: Synergism of CPT-11 and Apo2L/ TRAIL against two differentially sensitive human colon tumor xenografts. Oncology 74: 188-197, 2008.
10. Zhou W, Hu J, Tang H, Wang D, Huang X, He C and Zhu H: Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors. BMC Cancer 11: 485, 2011.
11. Cui DD, Huang Y, Mao SH, Chen SC, Qiu M, Ji LL and Yi C: Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7. Braz J Med Biol Res 42: 854-862, 2009.
12. Yeh YA, Herenyiova M and Weber G: Quercetin: synergistic action with carboxyamidotriazole in human breast carcinoma cells. Life Sci 57: 1285-1292, 1995.
13. Liu B, Peng XC, Zheng XL, Wang J and Qin YW: MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer 66: 169-175, 2009.
14. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McLaughlin MM, Srinivasula SM, Livi GP, Marshall LA, et al: Temperature- sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 275: 23319-23325, 2000. (Pubitemid 30646233)
15. Kruyt FA: TRAIL and cancer therapy. Cancer Lett 263: 14-25, 2008.
16. Johnstone RW, Frew AJ and Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798, 2008.
17. Koschny R, Walczak H and Ganten TM: The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med 85: 923-935, 2007. (Pubitemid 47282789)
18. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E and Dimanche-Boitrel MT: Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 61: 1645-1651, 2001. (Pubitemid 34292600)
19. Henson ES, Johnston JB and Gibson SB: The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma 49: 27-35, 2008. (Pubitemid 351146879)
20. Srivastava RK: TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3: 535-546, 2001.
21. Singh TR, Shankar S, Chen X, Asim M and Srivastava RK: Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63: 5390-5400, 2003. (Pubitemid 37139856)
22. McDonald ER III, Chui PC, Martelli PF, Dicker DT and El-Deiry WS: Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling. J Biol Chem 276: 14939-14945, 2001.
23. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E and Bhalla K: Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 96: 3900-3906, 2000.
24. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM and Repasky EA: Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 62: 5800-5806, 2002. (Pubitemid 35204738)
25. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK and Huang HJ: Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60: 847-853, 2000. (Pubitemid 30129513)
26. Liu W, Bodle E, Chen JY, Gao M, Rosen GD and Broaddus VC: Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol 25: 111-118, 2001. (Pubitemid 32682713)
27. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
28. Shinoura N, Sakurai S, Asai A, Kirino T and Hamada H: Caspase-9 transduction overrides the resistance mechanism against p53-mediated apoptosis in U-87MG glioma cells. Neurosurgery 49: 177-1877, 2001.
29. Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW and Lowe SW: Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284: 156-159, 1999. (Pubitemid 29282071)
30. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D and Ashkenazi A: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8: 274-281, 2002. (Pubitemid 34250106)
31. Nunez G, Benedict MA, Hu Y and Inohara N: Caspases: the proteases of the apoptotic pathway. Oncogene 17: 3237-3245, 1998. (Pubitemid 29043976)
32. Kaufmann SH and Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256: 42-49, 2000. (Pubitemid 30211165)
33. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D and Bhalla KN: Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 61: 759-763, 2001. (Pubitemid 32128643)
34. Gliniak B and Le T: Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 59: 6153-6158, 1999. (Pubitemid 30035636)